AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26542510 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of the GRS
Number of subjects: 3000
Study 23343686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent coronary sinus occlusion (iCSO) for 2 minutes
Number of subjects: 35
Study 23343686 — intervention group
Group type: COMPARATOR
Intervention: No iCSO (control)
Number of subjects: 35
Study 22338922 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise with weighted vests (EW, n = 24)
Number of subjects: 48
Study 22338922 — intervention group
Group type: COMPARATOR
Intervention: Walking exercise without weighted vests (E, n = 24)
Number of subjects: 48
Study 22338922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EW and E)
Number of subjects: 48
Study 19295387 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Number of subjects: 2
Study 19295387 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy under general anesthesia
Number of subjects: 2
Study 19295387 — intervention group
Group type: COMPARATOR
Intervention: Reference group (healthy, age-matched, sex-matched)
Number of subjects: 2
Study 17562253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin 40 mg/m(2) and vincristine 1.4 mg/m(2) (maximum, 2 mg) plus reduced‐dose dexamethasone 40 mg orally on days 1‐4 (DVd)
Number of subjects: 192
Study 17562253 — intervention group
Group type: COMPARATOR
Intervention: Conventional doxorubicin 9 mg/m(2) per day and vincristine 0.4 mg per day continuous intravenous infusion plus reduced‐dose dexamethasone (VAd)
Number of subjects: 192
Study 17562253 — intervention group
Group type: EXPERIMENTAL
Intervention: DVd
Number of subjects: 192
Study 14713761 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or adjuvant chemotherapy and radical cystectomy
Number of subjects: 64
Study 14713761 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor, interleukin-8, and MMP-9 expression
Number of subjects: 64
Study 12118900 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus 2 mg/day
Number of subjects: 1295
Study 12118900 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus 5 mg/day
Number of subjects: 1295
Study 12118900 — intervention group
Group type: EXPERIMENTAL
Intervention: statins and fibrates
Number of subjects: 1295
Study 12118900 — intervention group
Group type: COMPARATOR
Intervention: Framingham risk model
Number of subjects: 1295
Study 9717677 — intervention group
Group type: EXPERIMENTAL
Intervention: OspA vaccine (30-microgram dose)
Number of subjects: 1634
Study 9717677 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1634
Study 7867131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (52-mumol or 50,000 IU)
Number of subjects: 2067
Study 7867131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067
Study 2650588 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 to 20 mg oral nifedipine
Number of subjects: 30
Study 2650588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 336013 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% sodium fluorescein solution
Number of subjects: 83
Study 336013 — intervention group
Group type: COMPARATOR
Intervention: 10% sodium fluorescein solution
Number of subjects: 83
Study 31759688 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilkins score
Number of subjects: 60
Study 31759688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldrich score
Number of subjects: 60
Study 31759688 — intervention group
Group type: EXPERIMENTAL
Intervention: Selvester score
Number of subjects: 60
Study 31759688 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-derived myocardial salvage
Number of subjects: 60
Study 30985571 — intervention group
Group type: EXPERIMENTAL
Intervention: Modic Changes (MCs) group
Number of subjects: 204
Study 30985571 — intervention group
Group type: COMPARATOR
Intervention: No Modic Changes (-MC) group
Number of subjects: 204
Study 28934528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude home polysomnography (H-PSG)
Number of subjects: 10
Study 28934528 — intervention group
Group type: COMPARATOR
Intervention: Lower altitude laboratory polysomnography (L-PSG)
Number of subjects: 10
Study 26453527 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G needle
Number of subjects: 330
Study 22820718 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved dose of fospropofol (4.875 or 6.5 mg/kg depending on patient subgroup)
Number of subjects: 153
Study 22820718 — intervention group
Group type: COMPARATOR
Intervention: Weight-adjusted dose of fospropofol
Number of subjects: 153
Study 22820718 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved dose of fospropofol
Number of subjects: 153
Study 21477307 — intervention group
Group type: EXPERIMENTAL
Intervention: NIKE advertisement with the phrase 'LIGHT IT UP' (n = 205)
Number of subjects: 397
Study 21477307 — intervention group
Group type: COMPARATOR
Intervention: Neutral advertisement with reduced smoking imagery and the phrase 'GO FOR IT' (n = 192)
Number of subjects: 397
Study 18955670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy
Number of subjects: 526
Study 18955670 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 526
Study 16670647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene intervention
Number of subjects: 27
Study 16670647 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (5 mg)
Number of subjects: 27
Study 16670647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sleep hygiene and melatonin
Number of subjects: 27
Study 12795786 — intervention group
Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 60
Study 12795786 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR + Bio‐Oss (DBB‐)
Number of subjects: 60
Study 12795786 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR + Bio‐Oss impregnated with gentamicin (DBB+)
Number of subjects: 60
Study 12795786 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery (RBF)
Number of subjects: 60
Study 10969261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat cereal (24 grams per day, 1.2 ± 0.9 g/kg/d)
Number of subjects: 10
Study 8771109 — intervention group
Group type: EXPERIMENTAL
Intervention: Autovac system with calcium binding resin anticoagulant
Number of subjects: 50
Study 8771109 — intervention group
Group type: EXPERIMENTAL
Intervention: Autovac system with acid citrate dextrose anti-coagulate (ACD‐A)
Number of subjects: 50
Study 8771109 — intervention group
Group type: COMPARATOR
Intervention: Standard drain (control group)
Number of subjects: 50
Study 1448821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 927
Study 1448821 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg twice daily
Number of subjects: 927
Study 3989764 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 74
Study 3989764 — intervention group
Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 74
Study 28916304 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of dilute mesenchymal stem cells (MSCs)
Number of subjects: 36
Study 28916304 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of concentrated mesenchymal stem cells (MSCs)
Number of subjects: 36
Study 28916304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26541647 — intervention group
Group type: EXPERIMENTAL
Intervention: Book reading
Number of subjects: 69
Study 26541647 — intervention group
Group type: COMPARATOR
Intervention: Toy play
Number of subjects: 69
Study 26541647 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in speech characteristics
Number of subjects: 69
Study 25402840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional optical microscopy
Number of subjects: 131
Study 25402840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase‐contrast microscopy
Number of subjects: 131
Study 23134837 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver alloy-coated catheter
Number of subjects: 7102
Study 23134837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofural-impregnated catheter
Number of subjects: 7102
Study 23134837 — intervention group
Group type: COMPARATOR
Intervention: PTFE-coated catheter (control group)
Number of subjects: 7102
Study 19716540 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 510
Study 19716540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 18550961 — intervention group
Group type: COMPARATOR
Intervention: C (Caffeine 300 mg)
Number of subjects: 9
Study 18550961 — intervention group
Group type: COMPARATOR
Intervention: C + E (Caffeine 300 mg + Ephedra 60 mg)
Number of subjects: 9
Study 18550961 — intervention group
Group type: COMPARATOR
Intervention: P (Placebo 300 mg)
Number of subjects: 9
Study 16210886 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily administration of fluticasone propionate (200 microg at night)
Number of subjects: 40
Study 16210886 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily administration of fluticasone propionate (100 microg in the morning and at night)
Number of subjects: 40
Study 15769705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethicon steel band in addition to standard osteosynthesis with 8 wire cerclages
Number of subjects: 0
Study 10896070 — intervention group
Group type: COMPARATOR
Intervention: Fiber-only comparison group
Number of subjects: 64
Study 10896070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber and biofeedback-assisted cultivated low arousal
Number of subjects: 64
Study 10896070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber, biofeedback, and cognitive-behavioral interventions
Number of subjects: 64
Study 10896070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber, biofeedback, cognitive-behavioral, and parental support
Number of subjects: 64
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]8‐OH‐DPAT binding in the hippocampus
Number of subjects: 0
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]8‐OH‐DPAT binding in the striatum
Number of subjects: 0
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: [3H]8‐OH‐DPAT binding in the frontal cortex
Number of subjects: 0
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP gamma S modulation in hippocampus and frontal cortex
Number of subjects: 0
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalent cation effects in striatum
Number of subjects: 0
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalent cation effects in hippocampus
Number of subjects: 0
Study 9017662 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalent cation effects in frontal cortex
Number of subjects: 0
Study 8336527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (40 mmol of sodium daily)
Number of subjects: 115
Study 8336527 — intervention group
Group type: COMPARATOR
Intervention: High sodium diet (120 mmol of sodium daily)
Number of subjects: 115
Study 8336527 — intervention group
Group type: EXPERIMENTAL
Intervention: K-canrenoate (200 mg/day increasing to 600 mg)
Number of subjects: 115
Study 8336527 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (25-50-100 mg every other day)
Number of subjects: 115
Study 8336527 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout period of 7 days from outpatient diuretic regimen
Number of subjects: 115
Study 3535972 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 26
Study 3535972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 29985433 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Triple Antithrombotic Therapy (TATT)
Number of subjects: 177
Study 29985433 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based Dual Antiplatelet Therapy (DAPT)
Number of subjects: 177
Study 26653111 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1 mg/m(2)/d
Number of subjects: 110
Study 26653111 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2)/d
Number of subjects: 110
Study 26653111 — intervention group
Group type: COMPARATOR
Intervention: Combined GH/GnRHa
Number of subjects: 110
Study 26653111 — intervention group
Group type: COMPARATOR
Intervention: GH only
Number of subjects: 110
Study 26653111 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 1 mg/m(2)/d with GnRHa
Number of subjects: 110
Study 26653111 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2)/d with GnRHa
Number of subjects: 110
Study 24727639 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures based on the Automobile NOx/PM law
Number of subjects: 618973
Study 24727639 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in ambient air pollution (NO2 and SPM)
Number of subjects: 618973
Study 24727639 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in ambient air pollution (NO2 and SPM)
Number of subjects: 618973
Study 24727639 — intervention group
Group type: COMPARATOR
Intervention: Non-enforced areas (control)
Number of subjects: 618973
Study 24727639 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in air pollutant concentrations
Number of subjects: 618973
Study 22781921 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression (PFD) surgery
Number of subjects: 167
Study 20852415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 20852415 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical embolectomy
Number of subjects: 0
Study 20852415 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based embolectomy
Number of subjects: 0
Study 18514906 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/d
Number of subjects: 70
Study 18514906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 70
Study 16162203 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 588
Study 16162203 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 588
Study 16162203 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 588
Study 12669270 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE gene I/D polymorphism (DD, ID, II genotypes) in patients with CHD
Number of subjects: 691
Study 12669270 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE gene I/D polymorphism in patients with diabetes mellitus
Number of subjects: 691
Study 11061069 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence (UI) prevalence
Number of subjects: 504
Study 11061069 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for UI
Number of subjects: 504
Study 11061069 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of UI by gender
Number of subjects: 504
Study 11061069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to seek treatment for UI
Number of subjects: 504
Study 8889418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 0.2 mg kg‐1 (group A)
Number of subjects: 48
Study 8889418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 0.7 mg kg‐1 (group B)
Number of subjects: 48
Study 8889418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 1 mg kg‐1 (group C)
Number of subjects: 48
Study 8889418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 1.4 mg kg‐1 (group D)
Number of subjects: 48
Study 1739325 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 937
Study 1739325 — intervention group
Group type: COMPARATOR
Intervention: Axillary temperature measurement
Number of subjects: 937
Study 6200173 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl CCNU and 5‐Fluorouracil
Number of subjects: 0
Study 6200173 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 0
Study 31340849 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive vascular occlusion stimulus (RVOS) applied twice daily (once on day 1) for up to 10 days or until ICU discharge
Number of subjects: 32
Study 31340849 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 32
Study 29486489 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand nebulization of acetylcysteine or salbutamol (n=471)
Number of subjects: 922
Study 29486489 — intervention group
Group type: COMPARATOR
Intervention: Routine nebulization of acetylcysteine with salbutamol (every 6 hours until end of invasive ventilation, n=473)
Number of subjects: 922
Study 29486489 — intervention group
Group type: COMPARATOR
Intervention: Routine nebulization (n=473)
Number of subjects: 922
Study 23181708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 60
Study 23181708 — intervention group
Group type: COMPARATOR
Intervention: petrolatum (placebo)
Number of subjects: 60
Study 23181708 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of autoantibodies
Number of subjects: 60
Study 23181708 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of autoantibodies
Number of subjects: 60
Study 23181708 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 60
Study 23181708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail involvement
Number of subjects: 60
Study 22807477 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dose of oral 17β-oestradiol (5-15 μg/kg per day for 2 years)
Number of subjects: 48
Study 22807477 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of oral 17β-oestradiol (0.2 mg daily for the first year, 0.5 mg daily for the second year)
Number of subjects: 48
Study 21225018 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone nasal spray (200 μg in each nostril) once a day
Number of subjects: 90
Study 21225018 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone nasal spray (200 μg in each nostril) plus cetrizine (10 mg) orally once a day
Number of subjects: 90
Study 21225018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray (200 μg in each nostril) plus montelukast (10 mg) orally once a day
Number of subjects: 90
Study 17681971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with ropivacaine 0.487% plus clonidine 5 microg ml(‐1) (Group RC)
Number of subjects: 87
Study 17681971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with ropivacaine 0.487% (Group R)
Number of subjects: 87
Study 17681971 — intervention group
Group type: COMPARATOR
Intervention: Bilateral superficial cervical plexus block with saline (Group P)
Number of subjects: 87
Study 15754237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar paravertebral nerve root infiltration
Number of subjects: 117
Study 15754237 — intervention group
Group type: COMPARATOR
Intervention: First treatment with lumbar paravertebral nerve root infiltration
Number of subjects: 117
Study 11999889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 119
Study 9949220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 26
Study 9949220 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 9949220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 9949220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine and Control
Number of subjects: 26
Study 7561228 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anesthetics (EMLA) (N = 49)
Number of subjects: 96
Study 7561228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 47)
Number of subjects: 96
Study 2358004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (12 patients)
Number of subjects: 26
Study 2358004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (14 patients)
Number of subjects: 26
Study 526399 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 526399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanidine
Number of subjects: 0
Study 526399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Labetalol + Bethanidine)
Number of subjects: 0
Study 526399 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 30606273 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS-WFM combination
Number of subjects: 69
Study 30606273 — intervention group
Group type: COMPARATOR
Intervention: Control group (equally intensive clinical treatment)
Number of subjects: 69
Study 30448355 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided treatment strategy
Number of subjects: 130
Study 30448355 — intervention group
Group type: COMPARATOR
Intervention: Usual care treatment strategy
Number of subjects: 130
Study 30448355 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided care
Number of subjects: 130
Study 30448355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 28658126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP 120-140 mm Hg) for 7 days
Number of subjects: 80
Study 28658126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP 140-180 mm Hg) for 7 days
Number of subjects: 80
Study 28658126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 80
Study 25802841 — intervention group
Group type: EXPERIMENTAL
Intervention: MFT‐8
Number of subjects: 16
Study 25802841 — intervention group
Group type: COMPARATOR
Intervention: MFT
Number of subjects: 16
Study 22946979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 20
Study 22946979 — intervention group
Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 20
Study 21653660 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 54
Study 21653660 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 54
Study 19267733 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine oral rinse
Number of subjects: 100
Study 19267733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100